{"id":6024,"date":"2017-03-02T04:20:57","date_gmt":"2017-03-02T09:20:57","guid":{"rendered":"https:\/\/medicarereport.org\/?p=6024"},"modified":"2017-03-01T11:23:01","modified_gmt":"2017-03-01T16:23:01","slug":"orphan-drug-sales-will-outpace-all-other-meds-thanks-to-high-prices","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=6024","title":{"rendered":"Orphan drug sales will outpace all other meds, thanks to high prices"},"content":{"rendered":"<p>(By Ed Silverman for ST<em>A<\/em>T)<\/p>\n<p><span class=\"big-cap\">A<\/span>s payers continue to foot the bill for orphan drugs, sales of these rare disease treatments are forecast to grow 11 percent over the next five years \u2014 to $209 billion. And this is more than twice the expected increase in sales of all other prescription medicines, according to a new analysis. <a href=\"https:\/\/www.statnews.com\/pharmalot\/2017\/02\/28\/orphan-drugs-prices\/?_hsenc=p2ANqtz--Fr6041nDhSF7gt2mCpk9jSFRK1duIUxjLY8pua-xmFvvEEc9nuQzpEOsbx7s53DUAbTZFSFGHkafwGRY73oytxXk9ZQ&amp;_hsmi=43601372\" target=\"_blank\">Continue reading article here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"stat-logo\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice<\/strong>: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Ed Silverman for STAT) As payers continue to foot the bill for orphan drugs, sales of these rare disease<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-6024","post","type-post","status-publish","format-standard","hentry","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6024"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6024\/revisions"}],"predecessor-version":[{"id":6025,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/6024\/revisions\/6025"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}